Abstract
Frequent complications of bone metastases include pain, pathologic fracture, hypercalcemia and spinal cord compression. Lytic bone metastases result from excessive activation of osteoclasts by tumor-produced cytokines. Aredia (pamidronate) is a potent bisphosphonate that inhibits osteoclast activation. In two dose-seeking phase I trials in patients with breast cancer and prostate cancer, repeated intravenous infusion of Aredia was shown to be safe and effective in reducing bone resorption and pain. In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i.v. every 4 weeks. Compared with placebo, treatment with Aredia was associated with a significant decrease in bone pain and in the incidence and time to development of all skeleton-related events. Data from two phase III breast cancer trials each involving 300 patients are now being analyzed. The newer bisphosphonates can safely be used together with standard anticancer therapy to provide effective palliation of symptoms caused by lytic bone metastases.
Similar content being viewed by others
References
Albright JA, Gillespie TE, Butaud TR (1986) Treatment of bone metastases. Semin Oncol 7:418–434
Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Cancer 72:3443–3452
Body JJ (1992) Bone metastases and tumor-induced hypercalcemia. Current Opin Oncol 4:624–631
Clemens MR, Fessele K, Heim ME (1993) Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 66:141–146
Coleman RE (1994) Therapeutic use of bisphosphonates in oncology. BMJ 309:1233
Coleman RE, Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19:79–103
Coleman RE, Rubens RD (1985) Bone metastases and breast cancer. Cancer Treat Rev 12:251–270
Coleman RE, Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55:61–66
Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, Ford JM (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized muticenter phase III trial. Ann Oncol 5 [Suppl 7]:S41–44
Coyler RA (1986) Surgical stabilization of pathologic neoplastic fractures. Curr Probl Cancer 10:118–168
Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C (1992) Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 10:591–598
Galasko CSB (1982) Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 169:20–27
Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74:2949–2955
Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745–751
Holten-Verzantvoort AT van, Zwinderman AH, Aaronson NK, Hermans J, Emmerik B van, Dam FS van, Bos B van den, Bijvoet OL, Cleton FJ (1991) The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544–549
Holten-Verzantvoort AT van, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, et al (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491–498
Hortobagyi GN, Libshitz HI, Seabold JE (1984) Osseous metastases of breast cancer. Clinical, biochemical, radiographic and scintigraphic evaluation of response to therapy. Cancer 53:577–582
Lipton A (1994) The role of pamidronate. Ann Oncol 5 [Suppl 7]:S25–26
Lipton A, Glover D, Harvey H, Grabelsky S, Zelenakas K, Macerata R, Seaman J (1994) Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 5 [Suppl 7]: S31–35
Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F, Pannuti F (1991) Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 48:97–101
Papapoulos SE, Holten-Verzantvoort AT van (1992) Modulation of tumour-induced bone resorption by bisphosphonates. J Steroid Biochem Mol Biol 43:131–136
Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59–65
Shapiro CL (1994) Bisphosphonates in breast cancer patients with skeletal metastases. Hematol Oncol Clin North Am 8:153–163
Thiebaud D, Leyvraz S, Fliedner V von, Perey L, Cornu P, Thiebaud S, Burckhardt P (1991) Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 27:37–41
Thurlimann B (1994) Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? Ann Oncol 5 [Suppl 7]:545–547
Tyrell CJ, Collinson M, Madsen EL, Ford JM, Coleman T (1994) Intravenous pamidronate: infusion rate and safety. Ann Oncol 5 [Suppl 7]: S27–29
Wasan HS, Waxman J (1993) Clodronate for multiple myeloma. Lancet 341:175–176
Author information
Authors and Affiliations
Additional information
Presented in part as an invited lecture at the 7th International Symposium: Supportive Care in Cancer, Luxembourg, 20–23 September 1995
Rights and permissions
About this article
Cite this article
Harvey, H.A., Lipton, A. The role of bisphosphonates in the treatment of bone metastases — the U.S. experience. Support Care Cancer 4, 213–217 (1996). https://doi.org/10.1007/BF01682343
Issue Date:
DOI: https://doi.org/10.1007/BF01682343